Publication Name	World Journal of Diabetes
Manuscript ID	40441
Country	Japan

Received	2018-06-25 00:04
Peer-Review Started	2018-06-25 03:23
To Make the First Decision	2018-07-09 08:07
Return for Revision	2018-07-11 01:59
Revised	2018-07-12 09:41
Second Decision	2018-08-22 07:00
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2018-08-26 23:46
Articles in Press	2018-08-26 23:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-10-09 02:55
Publish the Manuscript Online	2018-10-12 11:58

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Retrospective Cohort Study
Article Title	Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
Manuscript Source	Invited Manuscript
All Author List	Hidetaka Hamasaki and Yasuteru Hamasaki
Funding Agency and Grant Number
Corresponding Author	Hidetaka Hamasaki, MD, PhD, Doctor, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 8900046, Japan. hhamasaki78@gmail.com
Key Words	Type 2 diabetes mellitus; Dipeptidyl pep­tidase-4 inhibitor; Anagliptin; Linagliptin; Cholesterol
Core Tip	Whether a substantial clinical difference exists in the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters remains inconclusive. Although this study is a relatively small-scale, short duration, retrospective study, the findings of this study suggests that the efficacy of DPP-4 inhibitors on the blood pressure, lipid profile, and liver function differs between anagliptin and linagliptin.
Publish Date	2018-10-12 11:58
Citation	Hamasaki H, Hamasaki Y. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018; 9(10): 165-171
URL	http://www.wjgnet.com/1948-9358/full/v9/i10/165.htm
DOI	http://dx.doi.org/10.4239/wjd.v9.i10.165

Full Article (PDF)	WJD-9-165.pdf
Full Article (Word)	WJD-9-165.doc
STROBE Statement	40441-STROBE statement.pdf
Manuscript File	40441-Review.docx
Answering Reviewers	40441-Answering reviewers.pdf
Audio Core Tip	40441-Audio core tip.m4a
Biostatistics Review Certificate	40441-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	40441-Conflict-of-interest statement.pdf
Copyright License Agreement	40441-Copyright license agreement.pdf
Institutional Review Board Approval Form or Document	40441-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	40441-Language certificate.pdf
Peer-review Report	40441-Peer-review(s).pdf
Scientific Misconduct Check	40441-Scientific misconduct check.pdf
Scientific Editor Work List	40441-Scientific editor work list.pdf